Intrauterine Fetal Growth Restriction and Fetuin-B

NCT07869004 | Enrolling By Invitation

• 1 other identifier: 2026-310
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

\*\*Brief Summary\*\* This study aims to evaluate the relationship between fetuin-B levels and intrauterine growth restriction (IUGR). Maternal serum fetuin-B levels will be compared between pregnant women with IUGR and those with appropriate fetal growth. The study will also assess whether fetuin-B levels are associated with clinical and obstetric characteristics, fetal growth parameters, and Doppler findings. The findings may provide further insight into the potential role of fetuin-B in the pathophysiology and clinical assessment of IUGR.

Conditions

IUGR

Outcome Measures

Primary Outcomes (1)

• Maternal Serum Fetuin-B Level

  Maternal serum fetuin-B levels will be measured and compared between pregnant women with intrauterine growth restriction (IUGR) and pregnant women with appropriate-for-gestational-age (AGA) fetuses to evaluate the association between fetuin-B levels and IUGR.

  At the time of diagnosis of IUGR or at the corresponding gestational age in the control group. It is time between the 24th and 37th weeks of pregnancy.

Study Arms (2)

IUGR Group

Pregnant women diagnosed with intrauterine growth restriction (IUGR) according to established clinical and ultrasonographic criteria. Maternal serum fetuin-B levels, fetal growth parameters, and Doppler findings will be evaluated.

Other: measure fetuin b

Control Group (AGA)

Pregnant women with appropriate-for-gestational-age (AGA) fetuses and without evidence of intrauterine growth restriction. Maternal serum fetuin-B levels, fetal growth parameters, and Doppler findings will be evaluated.

Other: measure fetuin b

Interventions

measure fetuin b OTHER

No intervention is administered. This is an observational study in which maternal serum fetuin-B levels are measured and compared between pregnant women with intrauterine growth restriction (IUGR) and pregnant women with appropriate-for-gestational-age (AGA) fetuses.

Control Group (AGA); IUGR Group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of pregnant women with singleton pregnancies who are evaluated during pregnancy at the participating center. The study group will include pregnant women diagnosed with intrauterine growth restriction (IUGR) according to predefined fetal growth and Doppler criteria. The control group will consist of pregnant women with appropriate-for-gestational-age (AGA) fetuses without evidence of IUGR. Maternal serum samples will be collected from participants to measure fetuin-B levels, and clinical, obstetric, fetal biometric, and Doppler parameters will be evaluated.

You may qualify if:

• Pregnant women with a singleton pregnancy.
• Gestational age between \[X and Y\] weeks at the time of enrollment.
• Pregnant women diagnosed with intrauterine growth restriction (IUGR) according to predefined fetal growth and Doppler criteria for the study group.
• Pregnant women with an appropriate-for-gestational-age (AGA) fetus for the control group.
• Availability of maternal serum samples for fetuin-B measurement.
• Provision of written informed consent to participate in the study.

You may not qualify if:

• Multiple pregnancy.
• Major fetal congenital or chromosomal anomalies.
• Known maternal chronic diseases that may significantly affect fetal growth or fetuin-B levels, such as pre-existing diabetes mellitus, chronic hypertension, renal disease, or autoimmune disease.
• Maternal infection or other conditions associated with fetal growth restriction, when clinically relevant.
• Placental abnormalities that may independently affect fetal growth.
• Pregnancies with incomplete clinical, laboratory, ultrasonographic, or Doppler data.
• Inability or unwillingness to provide informed consent.

Sponsors & Collaborators

• Karadeniz Technical University: lead

Study Sites (1)

Karadeniz technical university, school of medicine

Akçaabat, Trabzon, (530) 548 04 97, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITH DNA

Maternal peripheral venous blood samples will be collected from pregnant women for the assessment of fetuin-B levels and, if applicable, molecular/genetic analyses. The samples contain genomic DNA derived from maternal blood cells.

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: assistant professor

Study Record Dates

• First Submitted: September 30, 2026
• First Posted: October 9, 2026
• Study Start (Estimated): October 30, 2026
• Primary Completion (Estimated): January 30, 2027
• Study Completion (Estimated): February 28, 2027
• Last Updated: October 9, 2026

Record last verified: 2026-10

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)